Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 21Triple Negative Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Breast Neoplasms 17Advanced Solid Tumor 17Stomach Neoplasms 14Melanoma 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Urinary Bladder Neoplasms 5Rectal Neoplasms 5Esophageal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Cyclophosphamide 2toripalimab 1pembrolizumab 1fludarabine 1apatinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Heavy Ion Radiotherapy 1Drug Therapy 1Doxorubicin 1Cisplatin 1Carboplatin 1AP 1903 reagent 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thymic epithelial tumor × toripalimab × Clear all
NCT04667793 2023-04-04

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Unknown
15 enrolled

Thymic epithelial tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡